Ionis Pharmaceuticals Statistics
Share Statistics
Ionis Pharmaceuticals has 157.90M shares outstanding. The number of shares has increased by 8.33% in one year.
| Shares Outstanding | 157.90M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.12% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 145.55M |
| Failed to Deliver (FTD) Shares | 50 |
| FTD / Avg. Volume | 0% |
Short Selling Information
The latest short interest is 10.53M, so 6.67% of the outstanding shares have been sold short.
| Short Interest | 10.53M |
| Short % of Shares Out | 6.67% |
| Short % of Float | 7.23% |
| Short Ratio (days to cover) | 6.91 |
Valuation Ratios
The PE ratio is -19.75 and the forward PE ratio is -10.1.
| PE Ratio | -19.75 |
| Forward PE | -10.1 |
| PS Ratio | 9.18 |
| Forward PS | 5.8 |
| PB Ratio | 18.71 |
| P/FCF Ratio | -21.56 |
| PEG Ratio | n/a |
Enterprise Valuation
Ionis Pharmaceuticals Inc. has an Enterprise Value (EV) of 8.30B.
| EV / Earnings | -22.66 |
| EV / Sales | 10.54 |
| EV / EBITDA | -36.08 |
| EV / EBIT | -23.46 |
| EV / FCF | -24.73 |
Financial Position
The company has a current ratio of 5.9, with a Debt / Equity ratio of 3.76.
| Current Ratio | 5.9 |
| Quick Ratio | 5.83 |
| Debt / Equity | 3.76 |
| Total Debt / Capitalization | 78.99 |
| Cash Flow / Debt | -0.21 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.95% and return on capital (ROIC) is -21.08%.
| Return on Equity (ROE) | -0.95% |
| Return on Assets (ROA) | -0.12% |
| Return on Capital (ROIC) | -21.08% |
| Revenue Per Employee | 849.67K |
| Profits Per Employee | -395.13K |
| Employee Count | 927 |
| Asset Turnover | 0.26 |
| Inventory Turnover | 0.32 |
Taxes
| Income Tax | 32.32M |
| Effective Tax Rate | -0.1 |
Stock Price Statistics
The stock price has increased by -35.96% in the last 52 weeks. The beta is 0.39, so Ionis Pharmaceuticals 's price volatility has been higher than the market average.
| Beta | 0.39 |
| 52-Week Price Change | -35.96% |
| 50-Day Moving Average | 36.29 |
| 200-Day Moving Average | 41.35 |
| Relative Strength Index (RSI) | 36.31 |
| Average Volume (20 Days) | 1.41M |
Income Statement
In the last 12 months, Ionis Pharmaceuticals had revenue of 787.65M and earned -366.29M in profits. Earnings per share was -2.56.
| Revenue | 787.65M |
| Gross Profit | 778.51M |
| Operating Income | -353.73M |
| Net Income | -366.29M |
| EBITDA | -230.01M |
| EBIT | -353.73M |
| Earnings Per Share (EPS) | -2.56 |
Balance Sheet
The company has 399.27M in cash and 1.45B in debt, giving a net cash position of -1.05B.
| Cash & Cash Equivalents | 399.27M |
| Total Debt | 1.45B |
| Net Cash | -1.05B |
| Retained Earnings | -1.80B |
| Total Assets | 3.08B |
| Working Capital | 2.41B |
Cash Flow
In the last 12 months, operating cash flow was -307.51M and capital expenditures -28.01M, giving a free cash flow of -335.52M.
| Operating Cash Flow | -307.51M |
| Capital Expenditures | -28.01M |
| Free Cash Flow | -335.52M |
| FCF Per Share | -2.35 |
Margins
Gross margin is 98.84%, with operating and profit margins of -44.91% and -46.5%.
| Gross Margin | 98.84% |
| Operating Margin | -44.91% |
| Pretax Margin | -42.4% |
| Profit Margin | -46.5% |
| EBITDA Margin | -29.2% |
| EBIT Margin | -44.91% |
| FCF Margin | -42.6% |
Dividends & Yields
IONS does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -7.83% |
| FCF Yield | -6.5% |
Analyst Forecast
The average price target for IONS is $62, which is 89.7% higher than the current price. The consensus rating is "Buy".
| Price Target | $62 |
| Price Target Difference | 89.7% |
| Analyst Consensus | Buy |
| Analyst Count | 17 |
Scores
| Altman Z-Score | 1.25 |
| Piotroski F-Score | 5 |